HONG KONG, Feb. 1, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announces that it has entered into a memorandum of...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]anslational-medicine-lab-in-ho